Melanie Lee, Executive Vice President UCB,
President UCB NewMedicines will leave UCB at the end of August 2009
Brussels (Belgium), 20 May 2009 - press release regulated information
- UCB announced today, that Dr. Melanie Lee, Executive Vice President
UCB and President UCB NewMedicines will leave UCB at the end of
August 2009 and pursue other interests. Upon her departure from UCB,
Melanie Lee will join the Scientific Advisory Board of UCB.
"I want to thank Melanie Lee for her strong contribution to the
growth of UCB and before that, Celltech. In 2008, Melanie and her
team put in place the foundations of an innovative organization named
UCB NewMedicines, UCB's discovery research through to 'proof of
concept' organization. We are all committed to make this new
organization a leading edge discovery engine," Roch Doliveux, CEO
Melanie Lee has led both the discovery and research and development
organizations. She has served for six years as a Board Director with
Celltech and five years on UCB's Executive Committee, and has worked
tirelessly through four integrations.
In 2008, she put in place the structure for a new research
organization - UCB NewMedicines - designed to maximize internal and
external skills and technologies from discovery research through
'proof of concept'.
UCB has initiated an external search for a new individual to lead UCB
NewMedicines. The new President UCB NewMedicines will move this
organization beyond its current achievements to deliver UCB's
For further information
Antje Witte, Corporate Communications & Investor Relations, UCB
T +32.2.559.9414, email@example.com
Nancy Nackaerts, External Communications, UCB
M: +32 473 86 44 14, firstname.lastname@example.org
Notes to the editor:
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of EUR 3.6 billion
in 2008. UCB is listed on Euronext Brussels (symbol: UCB).
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.
For the pdf-version of this press release, please click on the link
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.